Singular Health Group Ltd Overview
| Item | Detail | Source |
|---|---|---|
| Legal name | Singular Health Group Limited | FY2026 Annual Report |
| Former names | None (Market Index records no former company names) | Market Index |
| ABN / ACN | ABN 58 639 242 765 / ACN 639 242 765 | FY2026 Appendix 4E |
| Founding | Technology origins in 2017 (MedVR, developed by Perth oncologist Dr Jason Tan) | Stockhead IPO coverage, Feb 2021 |
| Operating subsidiary | Singular Health Pty Ltd, incorporated 18 September 2019 | FY2022 Appendix 4E |
| Listed parent | Incorporated 20 February 2020 | FY2023 Annual Report, Note 1 |
| Incorporation jurisdiction | Western Australia, Australia (public company limited by shares) | FY2026 Annual Report |
| Registered office | Level 5, 191 St Georges Terrace, Perth WA 6000 | FY2026 Annual Report |
| Principal place of business | E3 and E4, 661 Newcastle Street, Leederville WA 6007 | FY2026 Annual Report |
| Exchange / ticker | ASX: SHG (also shown as CHIA:SHG, i.e. trades on Cboe Australia) | FY2026 AR; Simply Wall St |
| ISIN | — | — |
| CUSIP | Not applicable (no US listing) | — |
| Fiscal year end | 30 June | FY2026 AR |
| IPO | 12 February 2021; A$6.0M raised via 30M shares at A$0.20 | Squire Patton Boggs, Feb 2021 |
| Employees (latest and 3-year trend) | Not publicly disclosed. Employee benefits expense was A$3.24M in FY2026, A$1.70M in FY2025 and A$1.08M in FY2024 (continuing operations), which implies a small but growing team. | FY2025 and FY2026 ARs |
| Auditor | Pitcher Partners BA&A Pty Ltd, Perth (FY2025 and FY2026; lead partner Paul Mulligan). FY2023 auditor was Nexia Perth Audit Services. | FY2023, FY2025 and FY2026 ARs |
| Company secretary | Steven Wood (Automic Group) | FY2026 AR |
| Share registry | Automic Registry Services | FY2026 AR |
| Bankers | National Australia Bank (FY2025–26); ANZ (FY2023) | FY2023 and FY2026 ARs |
| Solicitors | Squire Patton Boggs | FY2026 AR |
| Website | https://singular.health; investor site https://investors.singular.health | ASX announcements |
Market capitalisation
| Item | Detail | Source |
|---|---|---|
| Recent quote | Bid A$0.160 / offer A$0.170 at last trade on 15 Oct 2026 | HotCopper |
| Shares on issue | — | FY2026 AR; option exercise notices |
| Estimated market capitalisation | ~A$52–57M (analyst estimate) | Derived |
| Earlier reference points | ~A$65–70M at A$0.20 (21 Jul 2026); ~A$66M (ROIC.ai) | Kalkine; ROIC.ai |
Singular Health is a Perth-based, US-focused micro-cap medical imaging software company. Its strategy is now centred on the 3DICOM platform, which it positions as interoperable imaging infrastructure that lets providers, payers, patients and educators locate, transfer, view and share medical scans across disparate PACS environments. The platform also renders those scans as interactive 3D models. The core commercial thesis is reducing duplicate imaging in the US healthcare system.
The company holds two FDA 510(k) Class II clearances:
-
3DICOM MD desktop, October 2022.
-
3DICOM MD Cloud, January 2026.
It also holds ISO 13485/MDSAP, ISO 27001, HIPAA and SOC 2 Type II credentials, and owns a proprietary Medical File Transfer Protocol (MFTP) with a favourable WIPO patentability opinion. Commercial traction remains early:
-
FY2026 contract revenue was A$1.43M, about 96% from the US, principally from one managed services organisation, Provider Network Solutions (PNS).
-
A non-binding US$2.55M Florida Medicaid repository MOU was signed on 29 September 2026.
The balance sheet is debt-free, with A$10.1M of cash and term deposits at 30 June 2026.
The company's own description (paraphrased from the FY2026 Annual Report)
The FY2026 Directors' Report defines the principal activities as:
-
development and commercialisation of the 3DICOM platform;
-
enterprise healthcare imaging and interoperability solutions;
-
education applications;
-
associated regulatory and product-development work.
The Board describes FY2026 as a year of transition from product development to commercial execution. It positions the Group as a provider of interoperable medical imaging infrastructure serving four market segments:
-
providers;
-
payers;
-
education;
-
government.
Segment reporting identifies a single operating segment: the provision and development of 3DICOM medical software (FY2026 AR, Note 4).
Independent characterisation
Singular Health is an early-commercial health-IT vendor. Its products sit at the "image exchange / zero-footprint viewer / enterprise imaging access layer" of the radiology value chain. It is not a PACS or RIS vendor, nor a diagnostic-AI developer. It overlays existing PACS through its 3DICOM Gateway and MFTP so that a primary care physician (PCP), a utilisation-management nurse at a health plan, or a patient can find and view prior studies wherever they were acquired.
The 3D volumetric rendering heritage (the original Volumetric Rendering Platform) is now a differentiating feature rather than the main value proposition. The economic pitch has shifted from "3D visualisation" to "avoid a repeat CT/MRI."
Business model and revenue model
| Revenue stream | Mechanism | FY2026 evidence | Source |
|---|---|---|---|
| Enterprise per-physician licences (subscription) | Annual licence per PCP, ~US$800 per doctor per year, sold through MSOs and provider networks | PNS: 750 licences deployed; US$500k licence payment received April 2026 | FY2026 AR; SmallCaps, Sep 2026 |
| Pilot and implementation fees | Upfront fees for bespoke pilots and integration | PNS US$300k upfront (June 2025), recognised from contract liabilities | FY2025 AR |
| Government and infrastructure project funding | State-funded project delivery and operation | Florida Medicaid repository MOU: US$2.55M (A$3.5M) total, ~85% to SHG, expected to be recognised in FY2027 | ASX, 29 Sep 2026 |
| Education subscriptions | Institutional access to 3DICOM EDU | Miami-Dade County Public Schools paid pilot | FY2026 AR |
| Direct-to-consumer and clinician subscriptions (Stripe) | Web subscriptions for MD, Patient and R&D tiers | A$51.4k in FY2026 (A$54.8k in FY2025) | FY2026 AR, Note 5 |
| Per-transfer micro-transactions | MFTP credits (historically US$1 per scan transfer) | — | FY2023 AR |
| Non-operating support | Australian R&D Tax Incentive refunds; interest on term deposits | R&D grant income A$471.5k; interest A$444.1k (FY2026) | FY2026 AR |
Mix (FY2026):
-
"Product sales" recognised over time (enterprise and licence services, all US) were A$1.377M, or 96.4% of contract revenue.
-
Stripe point-in-time sales (all Australia-booked) were A$51.4k, or 3.6%.
There is no hardware revenue since the September 2024 divestment of the Singular 3DP 3D-printing business.
Value-chain position and customers
| Customer type | Examples | Status |
|---|---|---|
| Managed Services Organisations (MSOs) and provider networks | Provider Network Solutions, Miami (serves 3.7M+ patients across Florida, Texas and Puerto Rico per FY2025 AR); Stellae Health (PNS network member) | Commercial (PNS); pilot MOU (Stellae) |
| Health plans and payers | Triple-S (Puerto Rico; GuideWell subsidiary) | Strategic discussions |
| Diagnostic imaging centres | Life Radiology, Miami | Live patient deployment; 230+ patients enrolled by 30 June 2026 |
| Education | Miami-Dade County Public Schools (M-DCPS); Florida International University (FIU) | Paid pilot; MOU |
| Government | Florida Medicaid Imaging Repository (via FIU); a multi-million-dollar project request to the US House of Representatives (Dec-2025 quarterly) | Non-binding MOU; request submitted |
| Individual clinicians, patients and researchers | Global web subscribers | Small, declining share |
End-markets served:
-
US healthcare (primary).
-
Australian healthcare (proof-of-concept proposals only).
-
Medical and allied-health education.
-
Historically, industrial 3D printing and mineral-resources visualisation (GeoVR); both have been exited.
Financial Narrative
Basis of the tables below:
-
Figures are taken from the audited annual reports.
-
FY2022 and FY2023 are as originally reported; FY2023 includes Singular 3DP from January 2023.
-
FY2024 is shown on the restated continuing-operations basis (FY2025 AR) for P&L lines, with net loss including discontinued operations.
-
FY2025 and FY2026 are as reported.
Income statement
Notes to the income statement table:
-
FY2021 (first, partial listed year): net loss A$4,456k; revenue and other income A$193.6k; EPS -6.02c (FY2025 AR five-year table).
-
FY2022 total revenue and other income is derived as A$54.0k revenue + A$363.7k R&D grant + A$7.6k interest. The FY2023 remuneration report shows A$54.0k for FY2022 "revenue and other income", which excludes grants.
-
FY2024 interest and finance income includes a non-cash A$302.2k unwind of convertible-note finance income.
-
Gross profit is blank where no cost of sales is reported. Software revenue carries no separately reported cost of sales, so gross margin is effectively not disclosed.
-
FY2022 and FY2023 weighted shares are derived from reported loss and EPS.
-
EBIT is derived as pre-tax income plus finance costs minus interest and finance income. EBITDA adds back D&A.
Margins and growth (%)
Revenue CAGR: contract revenue grew from A$54.0k (FY2022) to A$1,428.2k (FY2026), a 4-year CAGR of ~127%.
Balance sheet
Notes to the balance sheet table:
-
FY2021 closing cash was A$4,135.7k and closing equity A$5,082.3k (FY2023 AR comparatives).
-
FY2026 cash comprises A$2,362.0k cash at bank plus A$7,700.0k term deposits classified as financial assets.
-
FY2024 lease liabilities were partly within held-for-sale liabilities (A$261.0k), so the figure is left blank.
FY2025 net-loss typo: one FY2025 AR sentence states a net loss of A$6,736,210; the audited statements show A$6,376,210.
Cash flow
Notes to the cash flow table:
-
FY2023 borrowings comprise A$800k convertible notes plus A$419.2k R&D loan funding.
-
FY2026 receipts from customers of A$778.9k are well below recognised revenue of A$1,428.2k. The gap is explained by:
-
unwinding of the A$464.7k contract liability (cash received in FY2025);
-
a rise in receivables to A$859.4k.
-
-
Government grants received were nil in FY2026 versus A$354.5k in FY2025. The FY2026 R&D income of A$471.5k therefore appears to be accrued, with the cash refund expected after balance date (analyst inference from the cash flow statement).
Key ratios
ROIC, net debt/EBITDA and interest coverage are left blank because EBIT and EBITDA are negative and invested capital is negative (net cash exceeds equity less cash), so these ratios are not meaningful. FY2022 ROA is blank because FY2021 total assets were not available.
A cash conversion cycle is not meaningful for a software company with no inventory. The receivable-days figures include non-trade "other receivables" (for example, the 3DP contingent consideration), which inflates FY2025.
Commentary on trends, inflections and drivers
Revenue: an inflection from a tiny base.
-
FY2026 marks the first year of material contract revenue (A$1.43M).
-
It was driven almost entirely by the PNS Binding Enterprise Agreement:
-
recognition of the US$300k upfront payment previously held as a contract liability;
-
the US$500k licence payment received in April 2026 after deployment of 750 licences.
-
-
The Stripe-based direct subscription channel has been flat at roughly A$50–55k a year since FY2024. This confirms management's pivot away from direct-to-consumer towards enterprise and B2B2C channels.
Cost base: stepping up with US commercialisation.
-
Cash operating costs (payments to suppliers and employees) almost doubled, from A$3.43M in FY2025 to A$6.49M in FY2026.
-
Employee benefits rose 91% to A$3.24M, reflecting strategic hires including the US-based CCO (US$250k base salary).
-
R&D expenses rose 84% to A$1.19M.
-
Selling and marketing rose 177% to A$0.78M.
-
The reported loss was flat year on year (A$6.34M vs A$6.38M) only because non-cash share-based payments fell by A$1.18M, to A$2.09M.
Share-based payments: a structural feature.
-
Share-based payments have represented 22–51% of the annual net loss in every year since listing:
-
FY2022: A$2.66M, 44% of the loss;
-
FY2025: A$3.27M, 51%;
-
FY2026: A$2.09M, 33%.
-
-
This flatters cash burn relative to accounting losses but produces sustained dilution. Weighted shares rose about 3x, from 102.7M to 312.5M, between FY2022 and FY2026.
Balance sheet: transformed by FY2025 raisings.
-
In FY2023 the Group was close to insolvent:
-
equity of A$61.9k;
-
working-capital deficit of A$1.72M;
-
auditor's material-uncertainty paragraph on going concern.
-
-
About A$14.7M was raised in FY2025: Craig Sellars A$1.0M, the November 2024 placement A$3.7M, the June 2025 placement A$8.0M and option exercises.
-
As a result, the Group has been debt-free with A$10–14M of liquidity.
-
The FY2026 accounts no longer carry the material-uncertainty language present in FY2023 and FY2025.
Burn and runway.
-
FY2026 free cash flow was -A$5.45M, against A$10.06M of cash and term deposits at 30 June 2026. That implies roughly 22 months of runway at the FY2026 burn rate, consistent with the "about two years" runway cited in March-2026 quarterly coverage (Kalkine).
-
Potential runway extenders:
-
the US$2.55M Florida repository funding (~85% to SHG, expected in FY2027);
-
in-the-money options. About 25.3M options exercisable at A$0.08–0.10 could raise roughly A$2.2M.
-
7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING
Revenue by geography: notes and sources
Source: FY2025 AR Note 5 (FY2024 continuing comparatives) and FY2026 AR Note 5.
Segment x geography
With one segment, segment-by-geography equals the geographic table above. Within revenue type, all "product sales" (enterprise and services over time) were booked in the US in FY2025 and FY2026, and all Stripe subscription revenue was booked in Australia. Stripe revenue is processed by the Australian entity regardless of where the subscriber is located; the end-customer geography of Stripe subscribers is not disclosed.
Country level, fastest-growing and declining regions
United States (fastest-growing): revenue rose to A$1.38M in FY2026.
-
The PNS network spans Florida, Texas and Puerto Rico.
-
Other reference customers and pilots sit in Miami: Life Radiology and M-DCPS. FIU is also in Miami.
-
Drivers: the MSO channel, FDA clearances, a US-based CCO and the US subsidiary.
Puerto Rico: a pilot geography under the PNS programme and the location of Triple-S. Revenue is not separately disclosed.
Australia (declining): revenue fell from A$71.7k to A$51.4k between FY2024 and FY2026. Domestic activity is limited to proof-of-concept proposals to a state agency and a radiology stakeholder group (FY2025 AR). No domestic enterprise contract has been disclosed.
Rest of world: nil since FY2025. MedVR's earlier Asian and European installed base appears to have lapsed.
Singapore: SHG Health Pte Ltd was formed in June 2026. Its purpose has not been disclosed, and no revenue has been reported.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from contracts with customers (AUD K) | 54.0 | 616.1 | 90.8 | 203.1 | 1,428.2 |
R&D tax incentive / grant income (AUD K) | 363.7 | 414.2 | 843.2 | 354.5 | 471.5 |
Interest and finance income (AUD K) | 7.6 | 3.4 | 313.8 | 144.4 | 444.1 |
Total revenue and other income, continuing (AUD K) | 425.4 | 1,033.8 | 1,249.0 | 702.0 | 2,343.9 |
Cost of sales (AUD K) | 0 | 514.5 | — | — | — |
Gross profit (AUD K) | — | 101.6 | — | — | — |
Employee benefits expense (AUD K) | 1,718.1 | 1,825.3 | 1,078.9 | 1,699.8 | 3,240.1 |
Patent, R&D expenses (AUD K) | 598.0 | 587.7 | 417.7 | 643.8 | 1,187.3 |
Selling and marketing (AUD K) | 290.0 | 65.6 | 290.8 | 282.2 | 782.1 |
Share-based payments (AUD K) | 2,656.1 | 1,267.1 | 1,186.1 | 3,265.1 | 2,089.7 |
Depreciation and amortisation (AUD K) | 259.8 | 389.1 | 197.7 | 129.7 | 80.9 |
Finance costs (AUD K) | 12.9 | 477.6 | 97.8 | 10.4 | 9.9 |
Operating income / EBIT, derived (AUD K) | -5,980.7 | -4,916.1 | -3,094.5 | -6,396.1 | -6,774.7 |
EBITDA, derived (AUD K) | -5,720.9 | -4,527.0 | -2,896.8 | -6,266.4 | -6,693.8 |
EBITDA excluding share-based payments, derived (AUD K) | -3,064.8 | -3,259.9 | -1,710.7 | -3,001.3 | -4,604.1 |
Pre-tax income, continuing (AUD K) | -5,986.0 | -5,390.3 | -2,878.4 | -6,262.1 | -6,340.5 |
Net income attributable to owners (AUD K) | -5,986.0 | -5,390.3 | -4,924.7 | -6,376.2 | -6,340.5 |
EPS basic and diluted (A$ cents) | -5.83 | -4.90 | -3.08 | -2.69 | -2.03 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares, basic (millions) | 102.7 | 110.0 | 160.1 | 237.0 | 312.5 |
Margin metric
| Margin metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | — | 16.5 | — | — | — |
Operating (EBIT) margin, derived (%) | -11,076 | -798 | -3,408 | -3,149 | -474 |
EBITDA margin, derived (%) | -10,594 | -735 | -3,190 | -3,085 | -469 |
Net margin, continuing loss / revenue (%) | -11,085 | -875 | -3,170 | -3,083 | -444 |
Revenue growth YoY, contract revenue (%) | — | 1,041 | — | 124 | 603 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD K) | 2,140.2 | 2,998.6 | 2,350.8 | 14,207.5 | 11,235.9 |
Cash, equivalents and term deposits (AUD K) | 1,139.9 | 691.5 | 1,453.4 | 13,678.6 | 10,062.0 |
Trade and other receivables, current (AUD K) | 141.5 | 76.2 | 62.6 | 319.6 | 859.4 |
Short-term borrowings (AUD K) | 1.1 | 2,236.0 | 218.5 | 0 | 0 |
Long-term borrowings (AUD K) | 0 | 139.6 | 0 | 0 | 0 |
Lease liabilities, total (AUD K) | 84.5 | 134.9 | — | 0 | 110.0 |
Net debt / (net cash), incl. leases (AUD K) | -1,054.3 | 1,819.0 | -1,234.9 | -13,678.6 | -9,952.0 |
Goodwill and intangibles (AUD K) | 454.5 | 1,046.5 | 113.7 | 0 | 0 |
Total liabilities (AUD K) | 391.5 | 2,936.7 | 909.6 | 1,111.0 | 699.2 |
Contract liabilities / deferred revenue (AUD K) | 0 | 6.6 | 4.5 | 464.7 | 0 |
Total equity (AUD K) | 1,748.7 | 61.9 | 1,441.2 | 13,096.6 | 10,536.7 |
Issued capital (AUD K) | 9,526.7 | 11,977.6 | 16,430.8 | 29,919.4 | 32,656.2 |
Accumulated losses (AUD K) | -11,149.7 | -16,137.5 | -20,903.6 | -23,877.9 | -30,218.4 |
Working capital (AUD K) | 936.7 | -1,720.9 | 653.5 | 12,953.8 | 10,407.1 |
Net tangible assets per share (A$ cents) | — | — | 0.68 | 4.34 | 3.26 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD K) | 54.0 | 688.1 | 1,094.4 | 638.7 | 778.9 |
Operating cash flow (AUD K) | -2,905.8 | -2,463.2 | -2,440.3 | -2,341.4 | -5,302.4 |
Capex: PP&E (AUD K) | 11.8 | 22.5 | 73.6 | 29.2 | 143.8 |
Free cash flow, derived (AUD K) | -2,917.6 | -2,485.7 | -2,513.8 | -2,370.5 | -5,446.2 |
Equity issued, gross proceeds (AUD K) | 0 | 1,553.9 | 5,168.4 | 14,716.0 | 1,694.9 |
Borrowings raised (AUD K) | 0 | 1,219.2 | 811.7 | 0 | 0 |
Borrowings repaid (AUD K) | 0.4 | 0 | 2,482.8 | 205.1 | 0 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, net loss / average equity, derived (%) | -175 | -595 | -655 | -88 | -54 |
ROA, net loss / average assets, derived (%) | — | -210 | -184 | -77 | -50 |
Current ratio (x) | 3.50 | 0.36 | 2.42 | 12.66 | 18.19 |
Debt / equity, incl. leases (x) | 0.05 | 40.56 | 0.15 | 0 | 0.01 |
Asset turnover, revenue / average assets (x) | — | 0.24 | 0.03 | 0.02 | 0.11 |
Receivable days, current receivables / revenue x 365 (days) | — | 45 | 252 | 574 | 220 |
Income Statement
| Region (AUD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
United States of America | 0 | 148.3 | 1,376.8 |
Australia | 71.7 | 54.8 | 51.4 |
Rest of world | 19.1 | 0 | 0 |
Total contract revenue | 90.8 | 203.1 | 1,428.2 |
Margin Analysis (%)
| Region metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
US share of revenue (%) | 0 | 73.0 | 96.4 |
Australia share of revenue (%) | 79.0 | 27.0 | 3.6 |
US revenue growth YoY (%) | — | — | 828 |
Australia revenue growth YoY (%) | — | -24 | -6 |
Share price metric
| Share price metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at fiscal year end (AUD) | 0.096 | 0.036 | 0.10 | 0.38 | 0.21 |
Year-on-year change in FYE share price (%) | -69 | -63 | 178 | 280 | -45 |
Share Price & Returns
| Period | Performance | Basis |
|---|---|---|
1-year | About -45% | ~A$0.30 (20 Oct 2025, InvestSMART release price) to ~A$0.165 (15 Oct 2026). Kalkine cited about -46% over the year to 21 Jul 2026. |
3-year | About +300% or more | ~A$0.039 (15 Aug 2023 close, cited in the CG1 placement) to ~A$0.165 |
5-year | About -47% vs 30 Jun 2021; about -18% vs IPO price | — |
52-week range | A$0.17 – A$0.345 | As of 4 Sep 2026 (StockAnalysis); recent bids at A$0.16 suggest new lows |
Valuation Multiples
| Multiple | SHG | Pro Medicus (reference) | Mach7 (reference) |
|---|---|---|---|
Market cap | ~A$52–57M (estimated) | ~A$20bn (StockAnalysis) | — |
Enterprise value | ~A$42–47M (market cap less A$10.06M cash and term deposits) | — | — |
P/E | Not meaningful (loss) | Not computed | Not meaningful (loss) |
EV/EBITDA | Not meaningful (negative EBITDA) | Not computed | Not computed |
EV/Sales (FY2026) | ~30–33x | ~76x on market cap / FY2026 revenue (cash not deducted) | Not computed |
P/B | ~5.0–5.4x (equity A$10.54M) | Not computed | Not computed |
Price to book (StockAnalysis/PrimeStockFinder at A$0.18) | 4.86x | — | — |
Capital Markets
| Item | Detail |
|---|---|
Dividend history and policy | No dividend has ever been paid or declared (FY2021–FY2026); none is expected while the company is loss-making |
Buybacks | None authorised or executed |
Credit ratings | None (Moody's, S&P and Fitch do not rate the company) |
Debt maturity profile | No borrowings. Lease liabilities of A$110.0k (A$16.1k current; A$93.9k non-current) at 30 Jun 2026. Convertible notes and R&D loans were fully repaid by FY2025. |
Capital Instruments
| Instrument | Number | Terms |
|---|---|---|
Unlisted options | 76,752,772 | Exercise prices A$0.08 – A$0.55; expiries Feb 2027 – Nov 2029 |
of which A$0.08 | 17,562,500 | Expire 8 Dec 2027 |
of which A$0.10 | 7,727,272 | Expire 9 Feb 2027 |
of which A$0.15 | 18,463,000 | Expire Jul 2027 – Feb 2028 |
of which A$0.25 | 17,000,000 | Expire Apr 2028 – Apr 2029 |
of which A$0.55 | 16,000,000 | Expire Jun 2028 – Nov 2029 |
Performance rights | 10,000,000 | CEO; vested; expire 30 Jun 2028 |
Share Price & Returns by Date
| Date | Raise | Price (AUD) |
|---|---|---|
Feb 2021 | IPO A$6.0M | 0.20 |
Aug 2022 | Convertible notes A$0.8M | — |
Apr–May 2023 | Placement A$1.45M | ~0.055 |
Aug 2023 | CG1 strategic placement A$0.5–0.85M | 0.055 |
Feb 2024 | Placement A$4.05M | — |
Jul 2024 | Sellars A$1.0M | — |
Nov 2024 | Placement A$3.7M | 0.09 |
Jun 2025 | Placement A$8.0M | 0.35 |
Catalyst Details
| Catalyst | Expected timing | Why it matters |
|---|---|---|
PNS licence renewal and expansion | Overdue (was due Q3 CY2026) | Core recurring revenue |
Definitive Florida Medicaid repository agreement and first cash receipts | FY2027 (H1 CY2027 likely) | Converts the MOU into binding revenue |
Triple-S (or other payer) contract | Undated | First health-plan logo; validates the UM/RBM thesis |
AGM (late 2026) | Per notice of 6 Oct 2026 | Remuneration and option resolutions; board renewal |
Sep-2026 and Dec-2026 quarter Appendix 4C reports | Late Oct 2026; late Jan 2027 | Receipts versus burn |
Stellae Health pilot outcomes | FY2027 | PNS-network replication |
M-DCPS cohort results and conversion to ARR | FY2027 | Education vertical; the STI KPI is more than US$300k ARR |
HITRUST certification | Undated | Enterprise payer procurement requirement |
MFTP national-phase grants | Rolling | IP defensibility |
Option exercises (A$0.08 tranche expiring Dec 2027) | Through 2027 | Non-dilutive-equivalent funding of ~A$1.4M |
H1 FY2027 Appendix 4D | Feb 2027 | First half including SIS-US consolidation |
Executive Leadership
Board of Directors
| Name | Role | Tenure | Background | Education | Other listed boards |
|---|---|---|---|---|---|
Howard Digby | Non-Executive Chairman | Board since listing (fees reported from 27 Jan 2021) | IBM; senior roles at Adobe and Gartner; 12 years in Hong Kong, ending as Regional MD of The Economist Group; former Executive Editor, WA Business News; consultant to Forrest Capital | BEng (Hons), University of Western Australia | Elsight (ELS), 4DS Memory (4DS); formerly Spenda (resigned 21 Nov 2024) |
Denning Chong | Managing Director and CEO; co-founder | Director since incorporation; NED until 14 Apr 2023; Interim CEO/MD from 14 Apr 2023; Executive Service Agreement from 15 Apr 2023 | Principal of James Chong Lawyers since 2004 (cross-border transactions and M&A); director of Mutual Limited (fund manager, >A$4bn FUM), Australian subsidiaries of SGX-listed Hiap Hoe, and Aloft Hotel Perth | LLB (Dist.), BCom | — |
Andrew Just | Non-Executive Director | Board since listing era | Former Regional Director Asia Pacific, Radiometer (Danaher); CEO of Aeris Environmental; 30 years with GE Healthcare, Danaher, Stryker and Cochlear | BEc, HEc, MBA, GAICD | — |
Executive Leadership Team
| Name | Role | Tenure / notes | Source |
|---|---|---|---|
Dr Martina Mariano (PhD) | Chief Operating Officer | CCO 9 Feb 2024 – 28 Feb 2025; COO from 1 Feb 2025. Earlier Global Partnerships Manager; led US conference outreach in 2022. Base salary A$230k for FY2026. | FY2025 and FY2026 ARs |
Paige Taylor | Chief Commercial Officer (US) | From 15 Sep 2025. Base US$250k; CY2026 target bonus of 100% of base; 3M options promised (strike no lower than A$0.55), not yet granted at 30 Jun 2026. | FY2026 AR |
Andre Rocha | Chief Quality Officer | Led the MD Cloud 510(k) submission | ASX, 28 Nov 2025 |
Steven Wood | Company Secretary | Principal at Automic Group; previously Grange Consulting | FY2026 AR |
Dr Ronny Low | Technical Advisor (radiologist) | Dec 2024 | FY2025 AR |
Dr Alex Alonso | US radiology adviser; founder of Life Radiology. Paid in shares (US$27k fee settled in shares at the 14-day VWAP after six months). | Jul 2025 | FY2025 AR |
Executive Leadership Team — Thomas Hanly
| Name | Former role | Exit / notes |
|---|---|---|
Thomas Hanly | CEO and MD | Departed 14 Apr 2023 |
Prof. Kwang Guan Tay | Executive Director, Innovation & Research | Resigned 24 Mar 2023 |
James Hill | COO | Resigned 27 Jun 2025 (employed from 4 Nov 2019) |
Sujana Karthik | CFO and Joint Company Secretary | Appointed May 2023 (Grange Consulting) |
Kyla Garic | CFO | FY2024–FY2025, services via Onyx Corporate. Not listed as KMP in FY2026. |
Directors' Remuneration
| Name | Salary and fees | Cash bonus | Annual leave | Super | Share-based | Total |
|---|---|---|---|---|---|---|
Howard Digby (NE Chair) | 72,500 | 0 | 0 | 8,700 | 60,089 | 141,289 |
Andrew Just (NED) | 62,500 | 0 | 0 | 7,500 | 60,089 | 130,089 |
Denning Chong (MD/CEO) | 250,000 | 135,000 | 30,592 | 30,000 | 1,051,965 | 1,497,557 |
Martina Mariano (COO) | 220,000 | 0 | 24,373 | 26,400 | 0 | 270,773 |
Paige Taylor (CCO, from 15 Sep 2025) | 293,067 | 0 | 0 | 0 | 0 | 293,067 |
James Hill (resigned 27 Jun 2025; leave payout) | 14,526 | 0 | 0 | 3,974 | 0 | 18,500 |
Total KMP | 912,593 | 135,000 | 54,965 | 76,574 | 1,172,143 | 2,351,275 |
Related-Party Transactions
| Counterparty | Relationship | Amounts | Source |
|---|---|---|---|
James Chong & Co Pty Ltd | Associated with the CEO; legal services | A$5,309 (FY2026); A$9,042 (FY2025); A$50,959 (FY2023) | FY2023, FY2025 and FY2026 ARs |
Onyx Corporate (Kyla Garic) | CFO services | A$124,872 (FY2025) | FY2025 AR |
Re-Energise Digital (James Hill) | Marketing services | A$14,146 (FY2025) | FY2025 AR |
Marin & Sons Strategies LLC | Substantial holder and US adviser | 2,785,416 shares issued for consulting at A$0.305 (10 Sep 2025). Sold 4,166,667 SIS-US shares to SHG for US$175k (30 Jul 2026). | FY2026 AR |
Board & Management Changes
| Date | Change |
|---|---|
1 Feb 2025 | Mariano becomes COO |
27 Jun 2025 | Hill resigns as COO |
15 Sep 2025 | Taylor appointed CCO (US) |
19 Nov 2025 | AGM approves 6M new CEO options |
Major Shareholders
| Holder | Shares | % (approx.) | Source / date |
|---|---|---|---|
Marin and Sons Strategies LLC | 20,618,407 | 6.77% (substantial holder notice, 22 Aug 2025); ~6.6% (Simply Wall St) | InvestSMART; Simply Wall St, Nov 2025 |
Denning Chong (incl. indirect) | 17,429,719 | ~5.4–5.6% | FY2026 AR; Simply Wall St |
Klosters Holdings Pty Ltd | 8,150,000 | ~2.6% | Simply Wall St, Nov 2025 |
Chong Cheong | 7,065,754 | ~2.3% | Simply Wall St, Nov 2025 |
JLI Enterprises Pty Ltd | 6,640,869 | ~2.1% | Simply Wall St, Nov 2025 |
Ilia Manolev | 5,988,577 | ~1.9% | Simply Wall St, Nov 2025 |
Gaja Enterprises Ltd | 5,555,556 | ~1.8% | Simply Wall St, Nov 2025 |
Martina Mariano (COO) | 1,602,505 | ~0.5% | FY2026 AR |
Howard Digby (Chair) | 722,275 | ~0.2% | FY2026 AR |
Andrew Just (NED) | 336,364 | ~0.1% | FY2026 AR |
Targets & Commitments
| Initiative | Date | Description / status |
|---|---|---|
PNS strategic partnership | Nov 2024 – present | Four-phase programme: proof of concept, then pilot planning, then pilot, then national rollout. 750 licences deployed; contract renewal was due Q3 CY2026, with the outcome not yet disclosed. |
Cloud re-platforming | Mar 2024 – FY2025 | Complete migration to a zero-footprint cloud; UI/UX redesign; new clinical viewer aligned with diagnostic viewers |
3DICOM Gateway and Submission Portal | FY2025 | Hardware-free PACS connectivity |
Divestment of non-core 3DP | Sep–Oct 2024 | Focus on software |
US corporate build-out | Jul 2025 – Jul 2026 | US LLC formed; CCO hired; SIS-US joint vehicle with PNS (30%, stepped to ~60%) |
MD Cloud FDA clearance | Nov 2025 – Jan 2026 | Achieved in 40 days |
Payer expansion (Triple-S) | FY2025 – FY2026 | Enterprise imaging platform proposal covering Gateway, MD, Patient, AI-in-the-Cloud and UM/RBM workflows |
Provider reference site (Life Radiology) | Jul 2025 – present | Gateway plus Patient; 230+ patients enrolled |
Education (M-DCPS, FIU) | Mar 2026 – present | Paid pilot across five technical colleges for up to 150 students and instructors; FIU evaluation MOU |
Florida Medicaid Imaging Repository | FY2026 – Sep 2026 | Amended MOU: US$2.55M; 85% SHG share; five-year Florida-Medicaid exclusivity; follow-on annual state funding sought (FIU intends to seek more than US$3M a year) |
Federal outreach | Dec-2025 quarter | Multi-million-dollar project request submitted to the US House of Representatives; participation in the ONC consultation on diagnostic imaging interoperability |
HITRUST certification | FY2026 – ongoing | In progress |
Talk2View CRC-P application | FY2026 | AI-assisted visual communication integration; outcome uncertain |
athenahealth Marketplace | Dec-2025 quarter | Integration explored |
Stellae Health pilot | Post-FY2026 | Eight primary care practices within the PNS network |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with SHG | Scale / financials (where verified) |
|---|---|---|---|
Pro Medicus (ASX: PME), Visage 7 | Listed, Australia/US | Enterprise cloud-native diagnostic viewing in large US health systems | FY2026 revenue A$261.7M (+22.9%); underlying NPAT A$144.7M; underlying EBIT A$196.1M; cash and term deposits A$252.3M (FY2026 results, Aug 2026) |
Mach7 Technologies (ASX: M7T) | Listed, Australia/US | Vendor-neutral archive (VNA), enterprise viewer and image orchestration | FY2026 revenue A$27.9M (-17%); loss A$8.9M; 84% recurring revenue; cash A$19.9M (FY2026 results) |
PocketHealth (Toronto, private) | VC-backed | Patient-centric image exchange; community gateways; directly comparable to 3DICOM Patient and Gateway | US$33M Series B (2024); more than C$75M equity raised; 600+ hospitals and imaging centres; consumer subscription model (Goodmans; TechCrunch) |
Intelerad (private; includes Ambra Health and Life Image) | PE-backed | Cloud image exchange and enterprise imaging | — |
Nuance PowerShare (Microsoft) | Big-tech subsidiary | Legacy image exchange network | — |
Change Healthcare / Optum (UnitedHealth) | Payer-owned IT | Image exchange and RBM-adjacent workflows | — |
Purview (private) | Private | Image sharing and zero-footprint viewer | — |
Philips, GE HealthCare, Siemens Healthineers (enterprise imaging) | Multinational OEMs | Enterprise PACS, VNA and cloud viewers bundled with modalities | — |
Materialise (Mimics) and Synopsys Simpleware | Listed / segment | 3D segmentation and surgical planning (overlaps the legacy R&D tier) | — |
3D Systems (VSP), Axial3D | Listed / private | Virtual surgical planning and 3D anatomical modelling | — |
Free and low-cost DICOM viewers (OsiriX/Horos, RadiAnt, Weasis) | Open-source / low-cost | Clinician and patient viewing | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric (FY2026) | Singular Health (SHG) | Pro Medicus (PME) | Mach7 (M7T) |
|---|---|---|---|
Revenue (AUD Mn) | 1.43 | 261.7 | 27.9 |
Revenue growth YoY (%) | 507 (reported) / 603 (continuing) | 22.9 | -17.4 |
EBIT / operating margin (%) | -474 (derived) | ~75 (underlying EBIT / revenue) | Loss-making |
Net margin (%) | -444 | 55 (underlying NPAT basis) | -32 |
R&D intensity (%) | 83 (reported R&D line only) | — | — |
Cash and deposits (AUD Mn) | 10.1 | 252.3 | 19.9 |
Recent Developments
April – December 2025
| Date | Event | Significance |
|---|---|---|
| 15 Apr 2025 | Issue of incentive options to the CEO (10M at A$0.25) and NEDs, following GM approval on 19 Mar 2025 | Equity incentive alignment; dilution |
| 19 Jun 2025 | US$1.3M Binding Enterprise Agreement with PNS; A$8M placement at A$0.35 | First binding enterprise contract; transformational recapitalisation |
| 26 Jun 2025 | Quotation of 22.4M placement shares and 1.58M shares from conversions | Completes placement tranche |
| 27 Jun 2025 | COO James Hill resigns | Key-person change; Mariano already COO |
| 3 Jul 2025 | Dr Alex Alonso appointed US radiology adviser; Life Radiology deployment | US clinical credibility; reference site |
| 4 Jul & 7 Aug 2025 | US subsidiaries formed | US operating platform |
| 25 Jul 2025 | CEO buys A$100k of shares on market (~A$0.33) | Insider confidence |
| 18 Aug 2025 | SIS-US incorporated (SHG 30%, alongside PNS entities) | JV structure with anchor customer |
| 22 Aug 2025 | Marin and Sons Strategies becomes a substantial holder (6.77%) | US adviser becomes the largest holder |
| 29 Aug 2025 | FY2025 results: loss A$6.38M; cash and term deposits A$13.7M | Strong balance sheet |
| 10 Sep 2025 | 2,785,416 shares issued to Marin & Sons for consulting at A$0.305 | Share-settled adviser fees |
| 15 Sep 2025 | Paige Taylor appointed US CCO | US commercial leadership |
| 20 Oct 2025 | September-quarter Appendix 4C | Operational update |
| 19 Nov 2025 | AGM: remuneration report passes (93.04%); 6M CEO options approved | Governance |
| 28 Nov 2025 | FDA 510(k) submission for 3DICOM MD Cloud | Regulatory catalyst |
| Dec-2025 quarter | 250 MD licences deployed to PNS; Life Radiology moves from pilot to full patient deployment; next-generation Mobile app released; US House project request; athenahealth integration explored; operations continued through the US government shutdown | Commercial deployment begins |
| 22 Dec 2025 | CEO exercises 1.82M options at A$0.10 | Insider capital injection |
January – June 2026
| Date | Event | Significance |
|---|---|---|
| 13 Jan 2026 | FDA 510(k) clearance for 3DICOM MD Cloud (40-day review; adds X-ray and ultrasound) | Second FDA clearance; enables the cloud subscription model; shares rose more than 15% intraday (Webull) |
| 19–20 Jan 2026 | 1.72M options exercised at A$0.20 (A$344k; 12-month voluntary escrow) | Capital |
| 27 Jan 2026 | December-quarter Appendix 4C | Pipeline update; Florida MOU targeted by mid-2026 |
| 24 Feb 2026 | H1 FY2026 results: revenue +345%; net loss A$2.97M (+55%), including A$1.01M share-based payments | Cost step-up evident |
| Mar 2026 | 500 more licences deployed (750 total); Life Radiology Patient go-live; M-DCPS paid pilot executed; FIU MOU signed | Multi-vertical progress |
| 18 Mar 2026 | Chair buys A$10k of shares on market (~A$0.24) | Insider signal (small) |
| 9 Apr 2026 | Cleansing notice and option-exercise quotations | Capital |
| 22 Apr 2026 | US$500k licence payment received from PNS | First material cash licence receipt |
| 28 Apr 2026 | March-quarter Appendix 4C: cash A$10.015M, about two years' runway | Liquidity |
| 1 & 14 May 2026 | Further option exercises (~0.78M at A$0.10) | Minor capital |
| 10 Jun 2026 | Shares fall 7.3% to A$0.19 on thin volume with no news | Illiquidity |
| 12 Jun 2026 | SHG Health Pte Ltd (Singapore) incorporated | Possible Asia vehicle (purpose undisclosed) |
| 23–29 Jun 2026 | Option exercises, including 2.57M at A$0.10 (26 Jun) | Capital |
July – October 2026
| Date | Event | Significance |
|---|---|---|
| 16 Jul & 17 Aug 2026 | Further option exercises and quotations | Capital |
| 21 Jul 2026 | Shares fall ~9.1% to ~A$0.20; down ~46% over 12 months | Sentiment weakness |
| 30 Jul 2026 | SIS-US stake lifted to ~60% for US$175k; control obtained | Consolidation of the PNS-aligned vehicle |
| 31 Jul 2026 | June-quarter Appendix 4C: cash and term deposits ~A$10.1M; M-DCPS cohort for September | Liquidity and pipeline |
| 28–31 Aug 2026 | FY2026 Appendix 4E and Annual Report: revenue A$1.43M (+507%); loss A$6.34M. Appendix 4G and Corporate Governance Statement lodged 31 Aug. | Results |
| 29 Sep 2026 | Amended MOU with FIU: US$2.55M (A$3.5M) Florida Medicaid Imaging Repository; ~85% to SHG; five-year Florida-Medicaid exclusivity; IP retained | Largest single revenue opportunity to date, roughly 2x FY2026 revenue; non-binding |
| 30 Sep 2026 | Notice under ASX Listing Rule 3.13.1 (AGM date and director nominations). HotCopper also lists an Appendix 4E/Annual Report item dated 30 Sep 2026, likely a re-lodgement of the full report. | Corporate calendar |
| 1 Oct 2026 | Company presentation; investor webinar notice | Investor relations |
| 6 Oct 2026 | Notice of AGM and proxy form | AGM approaching (date in notice) |
| 8 Oct 2026 | Investor webinar (COO Martina Mariano) on the Florida MOU and operations | Investor relations |
| Post-FY2026 | Stellae Health pilot MOU (eight practices) | PNS network expansion |
| ~15 Oct 2026 | Last trade ~A$0.16–0.17 | Shares near 52-week lows |
Disclosure gaps
the outcome of the PNS licence renewal (due Q3 CY2026);
the Triple-S decision;
definitive Florida agreements.
litigation;
guidance revisions;
layoffs;
regulatory enforcement.



